Search results
Results from the WOW.Com Content Network
Hypergonadotropic hypogonadism (HH), also known as primary or peripheral/gonadal hypogonadism or primary gonadal failure, is a condition which is characterized by hypogonadism which is due to an impaired response of the gonads to the gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH), and in turn a lack of sex steroid production. [1]
It is used in hormone therapy for menopausal symptoms and low estrogen levels, hormone therapy for transgender people, and in hormonal birth control. [5] [4] [13] [14] It is also used in the treatment of prostate cancer. [13] The medication is taken by mouth or by injection into muscle or fat once every 1 to 4 weeks. [13] [14]
The side effects of cyproterone acetate (CPA), a steroidal antiandrogen and progestin, including its frequent and rare side effects, have been studied and characterized.It is generally well-tolerated and has a mild side-effect profile, regardless of dosage, when it used as a progestin or antiandrogen in combination with an estrogen such as ethinylestradiol or estradiol valerate in women.
Menopause symptoms — and how severe they are — vary from person to person. But in general, the hormonal changes that happen during menopause bring on a slew of physical and emotional side ...
Radiation therapy is commonly used in prostate cancer treatment. It may be used instead of surgery or after surgery in early-stage prostate cancer (adjuvant radiotherapy). Radiation treatments also can be combined with hormonal therapy for intermediate risk disease, when surgery or radiation therapy alone is less likely to cure the cancer.
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
Nice stressed that the symptoms women experience are real and treatments are available. Women with menopause symptoms ‘should be offered HRT as first-line treatment’ Skip to main content
Although promoted as a way of customizing treatment, hormone therapy does not require customization; [38] the use of testing to determine the number of hormones administered could result in the dose being higher than the minimum recommended level to alleviate symptoms, [2] [8] or the administration of unnecessary hormones to asymptomatic women ...